Journal of Clinical Immunology

, Volume 27, Issue 6, pp 557–562

Correction of Th1-dominant Cytokine Profiles by High-dose Dexamethasone in Patients with Chronic Idiopathic Thrombocytopenic Purpura

  • Chengshan Guo
  • Xiaoxia Chu
  • Yan Shi
  • Weidong He
  • Lizhen Li
  • Lin Wang
  • Yingxue Wang
  • Jun Peng
  • Ming Hou


To investigate the possible correcting of T helper (Th) cytokine profiles by high-dose dexamethasone (HD-DXM) therapy in chronic idiopathic thrombocytopenic purpura (ITP) with active disease, we determined the plasma levels of IFN-γ, IL-2, IL-4, IL-10, and TGF-β1 in 52 patients before and after oral administration of 40 mg/day DXM for four consecutive days. The cytokine levels were measured by enzyme-linked immunosorbent assay. The results showed that initial responses were reached in all patients and sustained response (SR) rate is 46.15%. The pretreatment plasma levels of both IFN-γ and IL-2 were significantly increased and those of IL-4, IL-10, and TGF-β1 significantly decreased, compared with those of the normal controls (P < 0.01), indicating a Th1-dominant cytokine profile typically found in ITP. After HD-DXM treatment, IFN-γ and IL-2 were decreased (P < 0.01), whereas IL-4 and IL-10 were increased (P < 0.05). There was no significant difference between the HD-DXM-treated patients and the normal controls (P > 0.05). TGF-β1 was also increased (P < 0.01) after HD-DXM treatment, but still lower than that of the normal controls (P < 0.05). During following-up, the cytokine profiles in the SRs remained stable compared to the posttreatment level (P > 0.05), but IFN-γ and IL-2 levels raised up, and IL-4, IL-10, and TGF-β1 levels reduced again in the relapsed patients (P < 0.01). Our data demonstrate that HD-DXM is an effective initial therapy for ITP, and the Th1 cytokine dominance could be corrected by HD-DXM.


Idiopathic thrombocytophenic purpura cytokines T helper lymphocyte dexamethasone 


  1. 1.
    Kuwana M, Kaburaki J Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest 1998;102:1393–402.PubMedCrossRefGoogle Scholar
  2. 2.
    Hedlund-Treutiger I, Wahlstrom J, Elinder G. Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:46–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci 1998;19:245–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991;78:2619–25.PubMedGoogle Scholar
  6. 6.
    Garcia-Suarez J, Prieto A, Reye E, Manzano L, Merino JL, Alvarez-Mon M. The clinical outcome of autoimmune thrombocytopenic purpura is related to their T-cell immunodeficiency. Br J Haematol 1993;84:464–70.PubMedGoogle Scholar
  7. 7.
    Ware RE, Howard TA. Elevated numbers of gamma delta(γδ+)T lymphocytes in children with immune thrombocytopenic purpura. J Clin Immunol 1994;14:237–47.PubMedCrossRefGoogle Scholar
  8. 8.
    Crossley AR, Dickinson AM, Proctor SJ, Calvert JE. Effects of interferon-á therapy on immune parameters in immune thrombocytopenic purpura. Autoimmunity 1996;24:81–100.PubMedGoogle Scholar
  9. 9.
    Erduran E, Aslan Y, Aliyazicioglu Y, Mocan H, Gedik Y. Plasma soluble interleukin-2 receptor levels in patients with idiopathic thrombocytopenic purpura. Am J Hematol 1998;57:119–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, et al. High Th1/Th2 ratio in patients with chronic autoimmune thrombocytopenic purpura. Eur J Haematol 2003;71:283–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004;103:2645–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Wali YA, Al Lamki Z, Shah W, Zacharia M, Hassan A. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002;19:329–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004;83:764–8.PubMedCrossRefGoogle Scholar
  15. 15.
    George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med 1998;30:38–44.PubMedGoogle Scholar
  16. 16.
    British Committee for Standards in Haematology. General Haematology Task Force: Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574–96.CrossRefGoogle Scholar
  17. 17.
    Gutierrez-Espindola GR, Morales-Polanco MR, Guerrero-Rivera S, Talavera JO, Sanchez-Valle E, Gomez-Morales E, et al. High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. Arch Med Res 2003;34:31–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura. A GIMEMA experience. Blood 2007;109(4):1401–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:61–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshimura C, Nomura S, Nagahama M, Ozaki Y, Kagawa H, Fukuhara S. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000;64:219–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Andersson PO, Olsson A, Wadenvik H. Reduced transforming growth factor-beta1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. Br J Haematol 2002;116:862–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res 2006;8:R81.CrossRefGoogle Scholar
  24. 24.
    Agarwal SK, Marshall GD Jr. Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 2001;21:147–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005;90:914–23.PubMedGoogle Scholar
  26. 26.
    Adcock IM, Brown CR, Gelder CM, Shirasaki H, Peters MJ, Barnes PJ. The effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 1995;37:C331.Google Scholar
  27. 27.
    Peng J, Liu CF, Liu D, Ren C, Li W, Wang Z, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003;101:2721–6.PubMedCrossRefGoogle Scholar
  28. 28.
    DeKruyff RH, Fang Y, Umetsu DT. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Chengshan Guo
    • 1
  • Xiaoxia Chu
    • 2
  • Yan Shi
    • 3
  • Weidong He
    • 4
  • Lizhen Li
    • 3
  • Lin Wang
    • 3
  • Yingxue Wang
    • 1
  • Jun Peng
    • 3
  • Ming Hou
    • 3
  1. 1.Department of HematologySecond Hospital of Shandong UniversityJinanChina
  2. 2.Department of HematologyYantai Yuhuangding HospitalYantaiChina
  3. 3.Department of HematologyQilu Hospital, Shandong UniversityJinanChina
  4. 4.Shandong Blood CenterJinanChina

Personalised recommendations